CHA Biotech signs material transfer deal with Chicago-based CanCure
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
CHA Biotech signed a material transfer deal with a U.S. biotech company to improve the efficacy of its natural killer cell-based cancer treatment.
The Kosdaq-listed biotech on Monday will bring in an antibody developed by CanCure, a Chicago-based immunotherapy drug developer, which targets a specific antigen expressed by cancer cells and can potentially help natural killer cells kill tumor cells.
CHA Biotech said that it will work with CanCure in order to increase the activity of natural killer cells and improve anti-cancer treatment efficacy using the U.S. company’s antibody substances.
“We are looking for various types of combination treatments with cancer immunotherapies and antibody drugs to expand and strengthen our natural killer cell treatment pipelines,” CHA Biotech CEO Lee Hyun-jung said.
BY SHIN HA-NEE [shin.hanee@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- [EXCLUSIVE] Taylor Mayor eyes Korea influx with Samsung's $17B chip plant arrival
- From a sky-high library to luxury fitness, Starfield Suwon beckons youthful explorers
- Adult performer who walked the streets wearing only a box remains defiant
- Nude model Ha Young-eun bares all with her first book
- Assaulted PPP lawmaker says attack 'should not happen to anyone else'
- [VIDEO] Diego Simeone's thoughts on Jurgen Klopp's announcement
- [NEWS IN FOCUS] From coffee to cosmetics: How Daiso went from humble dollar store to catch-all retail giant
- Seventeen encore 'Follow Again' to visit Korea, Japan in March
- North Korea fires cruise missiles from sea near Sinpo
- Samsung, LG strike unlikely TV partnership in battle with cut-price China